Gene expression profile testing for breast cancer and the use of chemotherapy, serious adverse effects, and costs of care

Breast Cancer Research and Treatment

Volumn 130, Issue 2, 2011, Pages 619-626

  Haas, Jennifer S ^a   Liang, Su Ying ^b   Hassett, Michael J ^c   Shiboski, Stephen ^b   Elkin, Elena B ^d   Phillips, Kathryn A ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Breast cancer; Genomics; Utilization

Indexed keywords

ALBUMIN; ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; PACLITAXEL;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER INVASION; CANCER TEST; CLINICAL FEATURE; CONTROLLED STUDY; DIARRHEA; FEMALE; GENE EXPRESSION PROFILING; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE POLICY; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MEDICAL RECORD; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; PROPENSITY SCORE; RECURRENCE RISK;

ADULT; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHEMOTHERAPY, ADJUVANT; DECISION MAKING; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MIDDLE AGED;

EID: 82955213000     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1628-6     Document Type: Article

References (34)

1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60(5):277-300
2. National Comprehensive Cancer Network (NCCN) Clinical practice guidelines in oncology: breast cancer v.1.20092009
3. Eifel P, Axelson JA, Costa J, Crowley J, Curran WJ Jr, Deshler A et al. (2001) National Institutes of Health Consensus Develop-ment Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 93(13):979-989
4. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687-1717
5. Warren JL, Yabroff KR, Meekins A, Topor M, Lamont EB, Brown ML (2008) Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst 100(12):888-897 (Pubitemid 351881955)
6. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M et al. (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817-2826 (Pubitemid 40051905)
7. Goldstein LJ, Gray R, Badve S, Childs BH, Yoshizawa C, Rowley S et al. (2008) Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 26(25): 4063-4071
8. Albain K, Barlow W, Shak S, Hortobagyi G, Livingston R, Yeh I et al. (2007) Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive
9. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W et al. (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24(23) 3726-3734 (Pubitemid 46622311)
10. Sotiriou C, Pusztai L (2009) Gene-expression signatures in breast cancer. N Engl J Med 360(8):790-800
11. Genomic Health 2005 Annual Report. Available from http://files. shareholder.com/downloads/GHDX/1288212664x0x237978/DBC CB2E0-6584-496A-ACB1- D67DDA497401/2005AR.pdf. Acces-sed 11 June 2011
12. Breastcancer.org. Ocotype DX Test (2011) Available athttp://www. breastcancer.org/symptoms/testing/types/oncotype-dx.jsp. Acces-sed 21 May 2011
13. Lyman GH, Cosler LE, Kuderer NM, Hornberger J (2007) Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. Cancer 109(6):1011-1018 (Pubitemid 46435378)
14. Oestreicher N, Ramsey SD, Linden HM, Mc Cune JS, van't Veer LJ, Burke W et al. (2005) Gene expression profiling and breast cancer care: what are the potential benefits and policy implica-tions? Genet Med 7(6):380-389 (Pubitemid 41139621)
15. Hornberger J, Lyman GH, Chien R (2010) Economic implica-tions of 21-gene recurrence score assay: US multicenter experi-ence. J Clin Oncol 28(22):e382
16. Hornberger J, Cosler LE, Lyman GH (2005) Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care 11(5):313-324 (Pubitemid 40646936)
17. Tsoi DT, Inoue M, Kelly CM, Verma S, Pritchard KI (2010) Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer. Oncologist 15(5):457-465
18. Klang SH, Hammerman A, Liebermann N, Efrat N, Doberne J, Hornberger J (2010) Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization. Value Health 13(4):381-387
19. Gold JM, Najita JS, Lester S, Richardson AL, Morganstern DE, Chen WY et al. (2009) Personalizing treatment in early-stage breast cancer: the role of standard clinical factors and genomic information in adjuvant chemotherapy decision making. ASCO Annual Meeting, Orlando, 2009
20. Ademuyiwa FO, Miller A, O'Connor T, Edge SB, Thorat MA, Sledge GW et al (2011) The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort. Breast Cancer Res Treat 126(3):797-802
21. Marchionni L, Wilson RF, Wolff AC, Marinopoulos S, Parmi-giani G, Bass EB et al. (2008) Systematic review: gene expres-sion profiling assays in early-stage breast cancer. Ann Intern Med 148(5):358-369 (Pubitemid 351665467)
22. Webber EM, Lin JS, Whitlock EP (2010) Oncotype DX tumor gene expression profiling in stage II colon cancer. Application: prognostic, risk prediction. PLoS Curr 2:RRN1177
23. Hassett MJ, O'Malley AJ, Pakes JR, Newhouse JP, Earle CC (2006) Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 98(16):1108-1117 (Pubitemid 44288785)
24. Liang SY, Phillips KA, Wang G, Keohane C, Armstrong J, Morris WM et al. (2011) Tradeoffs ofusing administrative claims and medical records to identify the use of personalized medicine for patients with breast cancer. Med Care 49(6):e1-e8
25. Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT et al. (2010) Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on che-motherapy: a retrospective analysis of a randomised trial. Lancet Oncol 11(1):55-65
26. Carlson B (2010) Payers try new approaches to manage molec-ular diagnostics. Biotechnol Healthcare 7(3):26-30
27. Deverka PA (2009) Pharmacogenomics, evidence, and the role of payers. Public Health Genomics 12(3):149-157
28. Klabunde CN, Potosky AL, Legler JM, Warren JL (2000) Development of a comorbidity index using physician claims data. J Clin Epidemiol 53(12):1258-1267 (Pubitemid 32007842)
29. Adams JL, Mehrotra A, Thomas JW, Mc Glynn EA (2010) Phy-sician cost profiling-reliability and risk of misclassification. N Engl J Med 362(11):1014-1021
30. Cepeda MS, Boston R, Farrar JT, Strom BL (2003) Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. Am J Epidemiol 158(3):280-287 (Pubitemid 36944422)
31. Lo SS, Mumby PB, Norton J, Rychlik K, Smerage J, Kash J et al. (2010) Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adju-vant breast cancer treatment selection. J Clin Oncol 28(10): 1671-1676
32. Cardoso F, Van't Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ (2008) Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 26(5):729-735 (Pubitemid 351264385)
33. Stukel TA, Fisher ES, Wennberg DE, Alter DA, Gottlieb DJ, Vermeulen MJ (2007) Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. JAMA 297(3):278-285 (Pubitemid 46143305)
34. Kerlikowske K, Cook AJ, Buist DS, Cummings SR, Vachon C, Vacek P et al. (2010) Breast cancer risk by breast density, menopause, and postmenopausal hormone therapy use. J Clin Oncol 28(24):3830-3837